The Hematopoietic Malignancies Program Area is composed of 21 members, spanning 6 Departments within UCLA. In the past competing cycle, investigators from this Program authored 372 publications, of which 104 (28%) were inter-programmatic and 59 (16%) intra-programmatic. 120 (32%) were placed in high-impact journals. 18 members of this Program Area used 7 of the currently funded JCCC Shared Resources. Current peer-reviewed funding for this program totals $6.1M of which $1.3M is awarded from NCI. The JCCC has provided the Hematopoeitic Malignancies Program with slightly more than $2.6M in support of its members and activities. These funds supported seed grants, recruitment and retention, salary support for program leadership and salary support for staff. The interests of program area members include the identification of the sites in which HSC emerge in the embryo, the delineation of lineage relationships between early stem and immature, lineage specified progenitor cells, the elucidation of intracellular signaling and transcriptional pathways that regulate blood cell development, and the effects of aging on blood cell production. This strength has in part evolved as a result of the recruitment of new faculty, the creation of the Eli and Edyth Broad Center of Regenerative Medicine and Stem Cell Research at UCLA (hereafter referred to as the UCLA Broad Stem Cell Center), and the considerable opportunities made possible by the California Institute for Regenerative Medicine (CIRM). A particularly significant development that will be detailed below is the use of human embryonic stem cells (hESC) to model hematopoiesis. Our basic and clinical program in lymphoma has been strengthened by the recruitment of two junior physician/scientists to the faculty. In this regard, new strategies to improve the efficacy of lymphoma vaccination will soon be introduced into clinical trials while a Phase I trial to target EBV-positive lymphomas is underway and has already enrolled patients. Thus, the further development of the lymphoma theme is a second major program goal, and several program area members are members of an inter-institutional lymphoma grant that has been submitted to the National Cancer Institute.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Wu, Sheng; Wong, Weng Kee; Crespi, Catherine M (2017) Maximin optimal designs for cluster randomized trials. Biometrics 73:916-926
Douaisi, Marc; Resop, Rachel S; Nagasawa, Maho et al. (2017) CD31, a Valuable Marker to Identify Early and Late Stages of T Cell Differentiation in the Human Thymus. J Immunol 198:2310-2319
Qi, Hangfei; Chu, Virginia; Wu, Nicholas C et al. (2017) Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein. Proc Natl Acad Sci U S A 114:2018-2023
Lu, Jianqin; Liu, Xiangsheng; Liao, Yu-Pei et al. (2017) Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun 8:1811
Castaneda, Julie T; Harui, Airi; Roth, Michael D (2017) Regulation of Cell Surface CB2 Receptor during Human B Cell Activation and Differentiation. J Neuroimmune Pharmacol 12:544-554
Casillas, Jacqueline; Goyal, Anju; Bryman, Jason et al. (2017) Development of a text messaging system to improve receipt of survivorship care in adolescent and young adult survivors of childhood cancer. J Cancer Surviv 11:505-516
Su, Yapeng; Wei, Wei; Robert, Lidia et al. (2017) Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. Proc Natl Acad Sci U S A 114:13679-13684
Demer, Linda L; Tintut, Yin; Nguyen, Kim-Lien et al. (2017) Rigor and Reproducibility in Analysis of Vascular Calcification. Circ Res 120:1240-1242
Kiyohara, M H; Dillard, C; Tsui, J et al. (2017) EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene 36:5793-5807
Dock, Jeffrey; Ramirez, Christina M; Hultin, Lance et al. (2017) Distinct aging profiles of CD8+ T cells in blood versus gastrointestinal mucosal compartments. PLoS One 12:e0182498

Showing the most recent 10 out of 721 publications